Obese Patients With or Without Comorbidities (RIO-North America)

Sanofi3,045 enrolled

Overview

To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

3,045

Conditions

Obesity Weight Loss

Interventions

Rimonabant (SR141716)DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

* Stable weight (variation of less than 5 kg within 3 months prior to screening visit) * BMI (Body Mass Index) of 30 or greater in patients with or without comorbidities, or BMI greater than 27 in patients with treated or untreated hypertension and/or treated or untreated dyslipidemia

Locations (51)

Outcomes

Primary Outcomes

Change in body weight

Secondary Outcomes

Metabolic parameters

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Radiant Research

Birmingham, Alabama, United States

Radiant Research

Phoenix, Arizona, United States

East Bay Clinical Trial Center

Concord, California, United States

Feighner Research Institute

San Diego, California, United States

Scripps Clinic

San Diego, California, United States

Diablo Clinical Research, Inc.

Walnut Creek, California, United States

Ranch View Family Medicine

Highlands Ranch, Colorado, United States

Longmont Medical Research Network

Longmont, Colorado, United States

Health Core, Inc.

Newark, Delaware, United States

George Washington Univ. Wieght Mmgt Program

Washington D.C., District of Columbia, United States

...and 41 more locations